165 related articles for article (PubMed ID: 35957524)
1. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.
Rocco MT; Akhter AS; Ehrlich DJ; Scott GC; Lungu C; Munjal V; Aquino A; Lonser RR; Fiandaca MS; Hallett M; Heiss JD; Bankiewicz KS
Mol Ther; 2022 Dec; 30(12):3632-3638. PubMed ID: 35957524
[TBL] [Abstract][Full Text] [Related]
2. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.
Richardson RM; Kells AP; Rosenbluth KH; Salegio EA; Fiandaca MS; Larson PS; Starr PA; Martin AJ; Lonser RR; Federoff HJ; Forsayeth JR; Bankiewicz KS
Mol Ther; 2011 Jun; 19(6):1048-57. PubMed ID: 21343917
[TBL] [Abstract][Full Text] [Related]
3. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.
Gimenez F; Krauze MT; Valles F; Hadaczek P; Bringas J; Sharma N; Forsayeth J; Bankiewicz KS
Neuroimage; 2011 Jan; 54 Suppl 1():S189-95. PubMed ID: 20080195
[TBL] [Abstract][Full Text] [Related]
4. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
Heiss JD; Lungu C; Hammoud DA; Herscovitch P; Ehrlich DJ; Argersinger DP; Sinharay S; Scott G; Wu T; Federoff HJ; Zaghloul KA; Hallett M; Lonser RR; Bankiewicz KS
Mov Disord; 2019 Jul; 34(7):1073-1078. PubMed ID: 31145831
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae.
Chittiboina P; Heiss JD; Lonser RR
J Neurosurg; 2015 May; 122(5):1173-9. PubMed ID: 25594325
[TBL] [Abstract][Full Text] [Related]
6. Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD; Ray-Chaudhury A; Kleiner DE; Ehrlich DJ; Scott G; Edwards NA; Goldstein DS; Hammoud DA; Hadaczek P; Van Laar VS; Graff SA; Herscovitch P; Lungu C; Hallett M; Lonser RR; Zaghloul KA; Bankiewicz KS
Mov Disord; 2024 May; ():. PubMed ID: 38718138
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.
Johnston LC; Eberling J; Pivirotto P; Hadaczek P; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 May; 20(5):497-510. PubMed ID: 19203243
[TBL] [Abstract][Full Text] [Related]
8. Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.
Su X; Kells AP; Salegio EA; Salegio EA; Richardson RM; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Forsayeth J; Bankiewicz KS
Mol Ther; 2010 Aug; 18(8):1490-5. PubMed ID: 20551915
[TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Su X; Kells AP; Huang EJ; Lee HS; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Penticuff J; Eberling J; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 Dec; 20(12):1627-40. PubMed ID: 19671001
[TBL] [Abstract][Full Text] [Related]
10. T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery.
Richardson RM; Gimenez F; Salegio EA; Su X; Bringas J; Berger MS; Bankiewicz KS
Neurosurgery; 2011 Jul; 69(1):154-63; discussion 163. PubMed ID: 21430597
[TBL] [Abstract][Full Text] [Related]
11. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.
Sanftner LM; Sommer JM; Suzuki BM; Smith PH; Vijay S; Vargas JA; Forsayeth JR; Cunningham J; Bankiewicz KS; Kao H; Bernal J; Pierce GF; Johnson KW
Exp Neurol; 2005 Aug; 194(2):476-83. PubMed ID: 16022872
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.
Christine CW; Bankiewicz KS; Van Laar AD; Richardson RM; Ravina B; Kells AP; Boot B; Martin AJ; Nutt J; Thompson ME; Larson PS
Ann Neurol; 2019 May; 85(5):704-714. PubMed ID: 30802998
[TBL] [Abstract][Full Text] [Related]
13. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
Kells AP; Forsayeth J; Bankiewicz KS
Neurobiol Dis; 2012 Nov; 48(2):228-35. PubMed ID: 22019719
[TBL] [Abstract][Full Text] [Related]
14. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.
Rocco MT; Akhter AS; Ehrlich DJ; Scott GC; Lungu C; Munjal V; Aquino A; Lonser RR; Fiandaca MS; Hallett M; Heiss JD; Bankiewicz KS
Mol Ther; 2023 Jul; 31(7):2296. PubMed ID: 37098347
[No Abstract] [Full Text] [Related]
17. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.
Yin D; Valles FE; Fiandaca MS; Bringas J; Gimenez F; Berger MS; Forsayeth J; Bankiewicz KS
Neuroimage; 2011 Jan; 54 Suppl 1():S196-203. PubMed ID: 19761848
[TBL] [Abstract][Full Text] [Related]
18. Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease.
Terse PS; Kells AP; Noker P; Wright JF; Bankiewicz KS
Int J Toxicol; 2021; 40(1):4-14. PubMed ID: 33131343
[TBL] [Abstract][Full Text] [Related]
19. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.
Eberling JL; Kells AP; Pivirotto P; Beyer J; Bringas J; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 May; 20(5):511-8. PubMed ID: 19254173
[TBL] [Abstract][Full Text] [Related]
20. Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus.
Brady ML; Raghavan R; Alexander A; Kubota K; Sillay K; Emborg ME
Stereotact Funct Neurosurg; 2013; 91(2):69-78. PubMed ID: 23344643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
